THERAZONE ApS: Financial statements 2012
CVR: 27255574
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
THERAZONE ApS (CVR 27255574) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -11,722 and a net result of DKK 192,648. Equity in the 2012 report amounted to DKK 130,724. The solvency ratio was 11.9%.
- Gross Profit
- DKK -11,722
- Profit/Loss
- DKK 192,648
- Equity
- DKK 130,724
- Total Assets
- DKK 1,094,806
Official annual report
Keep an eye on THERAZONE ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of August 20, 2012, MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of THERAZONE ApS.
As of August 20, 2012, JUT NR. 2180 A/S has stepped down as auditor of THERAZONE ApS.
As of May 3, 2012, JUT NR. 2180 A/S has been appointed auditor of THERAZONE ApS.
As of May 3, 2012, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of THERAZONE ApS.
About THERAZONE ApS
THERAZONE ApS is a Danish company of the type Anpartsselskab based in Dragør, founded in 2003. The company is registered under the industry Investering for egen regning. The management consists of Thomas Magnussen. The company is owned by Thomas Magnussen. According to the 2024 annual report, the company had an average of 2 employees. In 2024, the company reported a gross profit of DKK -255,949 and a net result of DKK 4,003,809 compared with DKK 2,462,806 the year before. Equity in the 2024 report amounted to DKK 44,842,105.